Glaxo Group Limited

Jon Graham Anthony Steadman

David Kenneth Dean

Daryl Simon Walter

Giancarlo Trani

Jorge Munoz-Muriedas

Mairi Sime

Rachel Elizabeth Anne Thewlis

Ian David Wall

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, Calkyl, Ccycloalkyl, Calkoxy, Calkoxy Calkyl, Cfluoroalkyl, halogen, NRR, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R, R, R, R, R, Rand Rare as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.

5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, Calkyl, Ccycloalkyl, Calkoxy, Calkoxy Calkyl, Cfluoroalkyl, halogen, NRR, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R, R, R, R, R, Rand Rare as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.

5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators

Growing community of inventors

Harlow, United Kingdom

Jon Graham Anthony Steadman